Company intelligence / Profile preview
BioGate Precision Medicine
Taipei, Taiwan
- Ownership
- Private
- Employees
- ~15
- Development stage
- Other
01
Overview
BioGate’s lead biologic BGX has shown, in preclinical models, the ability to suppress tumor growth, inhibit metastasis, and significantly prolong survival in animal models of pancreatic cancer. The company is planning a Phase I clinical trial application in Taiwan and with the US FDA. Its vaccine technology has produced high neutralizing antibody titers and CTL responses in animal models for COVID-19 and immunotherapy targets.
- Therapeutic areas
- OncologyInfectious DiseasesImmunology
- Modalities
- Monoclonal antibodyBiological productsVaccineSubunit vaccine
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on BioGate Precision Medicine.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioGate Precision Medicine.